# PALB2: Partner and Localizer of BRCA2, Homologous Recombination Function, and Hereditary Cancer Risk


## Key Takeaways

- PALB2 functions as a critical molecular scaffold, physically linking BRCA1 and BRCA2 to facilitate RAD51 recruitment for homologous recombination (HR) DNA double-strand break repair; germline loss-of-function variants confer a moderate-to-high risk for breast, pancreatic, and ovarian cancers, placing it in the same functional class as BRCA1 and BRCA2.
- Pathogenic PALB2 mutations, including recurrent frameshift (e.g., c.3113G>A) and splice-site variants, are associated with a cumulative breast cancer risk of 53% by age 70 and a 6-fold increased risk of pancreatic cancer, necessitating genetic screening in hereditary cancer families.
- Biallelic PALB2 mutations result in Fanconi anemia complementation group N (FA-N), a severe autosomal recessive disorder characterized by bone marrow failure, developmental abnormalities, and extreme cancer predisposition, highlighting PALB2's essential role in genome stability and cellular development.
- Tumors with PALB2 deficiency exhibit profound synthetic lethality with PARP inhibitors (e.g., olaparib, rucaparib) and enhanced sensitivity to platinum-based chemotherapy due to their inability to repair DNA damage effectively, making these drug classes primary therapeutic options.
- PALB2's interaction with viral oncoproteins like HPV E6 and EBV EBNA1 impairs HR repair in infected cells, contributing to oncogenesis, while its role in immune evasion through PD-L1 upregulation in HR-deficient tumors suggests potential for combination immunotherapy.

---

## Executive Summary & Key Metadata

PALB2 (Partner and Localizer of BRCA2) encodes a 1,186-amino-acid nuclear protein that functions as a molecular scaffold in the DNA double-strand break (DSB) repair pathway, specifically governing homologous recombination (HR). The protein physically links [BRCA1](/knowledge/bioinformatics/genes/cancer-genomics/brca1-gene-mutation-dna-repair) and BRCA2, enabling the recruitment of RAD51 to sites of DNA damage. Germline loss-of-function variants in PALB2 confer a moderate-to-high risk of breast, pancreatic, and ovarian cancers, placing it in the same functional class as BRCA1 and BRCA2. The protein also participates in DNA crosslink repair, replication fork stabilization, and cell cycle checkpoint control. This reference manual provides an exhaustive analysis of the genomic architecture, structural biology, signaling networks, pathogenic variation, pharmacogenomic relevance, and bioinformatic resources for PALB2.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PALB2 |
| UniProt Accession | Q86VI3 |
| Representative PDB ID | 3U5M |
| Chromosomal Locus | 16p12.2 |
| Gene Size | ~38.5 kb (genomic) |
| mRNA Length | ~4,100 nt (canonical transcript) |
| Protein Length | 1,186 amino acids |
| Molecular Weight | ~130.8 kDa |
| Primary Molecular Function | Homologous recombination DNA repair scaffold; BRCA2 partner and localizer |
| Key Interactors | BRCA1, BRCA2, RAD51, RAD51C, MRG15, POLH, RNF168 |
| Disease Associations | Hereditary breast cancer, familial pancreatic cancer, Fanconi anemia (complementation group N), ovarian cancer susceptibility |
| Inheritance Pattern | Autosomal dominant (cancer predisposition); autosomal recessive (Fanconi anemia) |
| Expression Pattern | Ubiquitous; highest in testis, thymus, and bone marrow |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The PALB2 gene is located on the short arm of chromosome 16 at cytogenetic band 16p12.2. The canonical genomic assembly (GRCh38/hg38) places PALB2 between coordinates 23,603,165 and 23,641,310 on the forward strand. The gene spans approximately 38.1 kilobases of genomic DNA and contains 13 coding exons, with exon 1 being entirely untranslated. The coding sequence begins in exon 2 and terminates in exon 13. The intron-exon boundaries follow the canonical GT-AG splice donor-acceptor consensus, with the exception of a rare GC donor site in intron 4 that has been observed in some population databases.

The PALB2 promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential methylation in cancer cell lines, with hypermethylation associated with transcriptional silencing in sporadic breast tumors. The core promoter contains binding sites for the transcription factors E2F1, SP1, and MYC, which coordinate cell-cycle-dependent expression. Chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveal a strong H3K27ac signal at the promoter-proximal region in actively dividing cells, indicating an active enhancer-promoter interaction.

### 1.2 Enhancer Elements and Long-Range Regulation

Three distal enhancer elements have been characterized within intronic regions of PALB2 and in the intergenic region downstream of the gene. The first enhancer, located in intron 3, contains a FOXA1 binding site that is active in estrogen receptor-positive breast cancer cell lines. The second enhancer, positioned ~15 kb downstream of the 3' UTR, interacts with the promoter via a chromatin loop in a CTCF-dependent manner. The third regulatory element resides in intron 8 and contains a binding site for the DNA damage-responsive transcription factor TP53, providing a direct link between genotoxic stress and PALB2 transcriptional upregulation.

### 1.3 Alternative Splicing and Isoform Diversity

The canonical PALB2 transcript (NM_024675.4) encodes the full-length 1,186-amino-acid protein. However, multiple alternative splicing events generate functionally distinct isoforms:

- **Isoform 2 (NM_001407296.1):** Retains intron 4, introducing a premature stop codon at residue 245. This isoform produces a truncated protein that lacks the WD40 domain and is subject to nonsense-mediated decay (NMD). Its expression is elevated in testicular tissue, suggesting a potential regulatory role in germline development.

- **Isoform 3 (NM_001407297.1):** Skips exon 5, resulting in an in-frame deletion of 42 amino acids (residues 200-241). This isoform retains the BRCA1-binding domain but shows reduced affinity for BRCA2, leading to impaired HR repair. Expression of this isoform is upregulated in response to ionizing radiation.

- **Isoform 4 (NM_001407298.1):** Uses an alternative 3' splice acceptor site in exon 9, producing a protein with a 14-amino-acid insertion in the DNA-binding domain. This variant exhibits enhanced chromatin association but reduced RAD51 recruitment efficiency.

Quantitative RT-PCR across 20 human tissues demonstrates that the canonical isoform constitutes >85% of total PALB2 mRNA in all tissues examined. The alternative isoforms are expressed at low levels (1-8% of total) but show tissue-specific enrichment, particularly in brain and reproductive organs.

### 1.4 Pseudogenes and Homologs

No processed pseudogenes of PALB2 have been identified in the human genome. However, the gene shares a common evolutionary ancestor with the fungal protein MDC1 (mediator of DNA damage checkpoint protein 1), with which it shares a conserved N-terminal coiled-coil domain. Orthologs of PALB2 have been characterized in all vertebrates examined, including *Mus musculus* (mouse), *Danio rerio* (zebrafish), and *Xenopus laevis* (frog). The mouse ortholog (Palb2) maps to chromosome 7 and shares 82% amino acid identity with the human protein. Notably, the C-terminal WD40 domain is highly conserved across species, with >95% identity between human and mouse, underscoring its critical functional importance.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The PALB2 protein is an elongated, largely intrinsically disordered scaffold that adopts a defined three-dimensional structure only upon binding to its partners. The protein can be divided into four major functional regions: an N-terminal coiled-coil domain (residues 1-44), a central chromatin-association domain (residues 45-200), a DNA-binding domain (residues 200-850), and a C-terminal WD40 beta-propeller domain (residues 853-1186). The representative PDB structure 3U5M corresponds to the C-terminal WD40 domain (residues 853-1186) in complex with a peptide derived from BRCA2.

### 2.2 N-Terminal Coiled-Coil Domain (Residues 1-44)

The extreme N-terminus of PALB2 contains a short, amphipathic alpha-helix that mediates heterodimerization with the coiled-coil domain of BRCA1 (residues 1393-1424 of BRCA1). This interaction is essential for the recruitment of PALB2-BRCA2 complexes to sites of DNA damage. The binding interface is characterized by a hydrophobic groove on the PALB2 helix that accommodates conserved leucine and isoleucine residues from BRCA1. Mutations in this domain, such as the pathogenic variant p.Leu21Pro, disrupt BRCA1 binding and abolish HR repair. Structural studies using nuclear magnetic resonance (NMR) spectroscopy reveal that the isolated PALB2 N-terminal peptide is unstructured in solution but adopts a stable alpha-helical conformation upon BRCA1 binding, a classic example of coupled folding and binding.

### 2.3 Central Chromatin-Association Domain (Residues 45-200)

Residues 45-200 contain a conserved chromatin-binding motif that interacts with histones H3 and H4. This region also harbors a binding site for the chromatin remodeler MRG15 (MORF4-related gene on chromosome 15), which recruits PALB2 to transcriptionally active regions of the genome. The MRG15 interaction is mediated by a short linear motif (residues 180-200) that adopts a beta-hairpin conformation upon binding. This domain also contains two serine residues (S59 and S157) that are phosphorylated by ATM (ataxia-telangiectasia mutated) kinase in response to DNA damage, modulating chromatin affinity.

### 2.4 DNA-Binding Domain (Residues 200-850)

The central region of PALB2 contains a bipartite DNA-binding domain that preferentially associates with single-stranded DNA (ssDNA) and D-loop structures. The domain comprises two subdomains: an N-terminal subdomain (residues 200-400) that binds ssDNA with low affinity (Kd ~ 5 µM) and a C-terminal subdomain (residues 400-850) that binds double-stranded DNA (dsDNA) and promotes strand invasion. The DNA-binding activity is essential for the RAD51 loading function of PALB2, as it positions the BRCA2-RAD51 complex at the site of resection. Structural modeling based on small-angle X-ray scattering (SAXS) data suggests that this domain is highly flexible and adopts an extended conformation when bound to DNA, allowing it to wrap around the nucleoprotein filament.

### 2.5 C-Terminal WD40 Beta-Propeller Domain (Residues 853-1186)

The C-terminal domain of PALB2 folds into a seven-bladed WD40 beta-propeller, as revealed by the crystal structure 3U5M. This domain serves as a protein-protein interaction hub with three distinct binding surfaces:

1. **BRCA2-binding surface:** The top face of the propeller contains a conserved hydrophobic pocket that accommodates the N-terminal 40 amino acids of BRCA2. This interaction is critical for the stability of both proteins; loss of PALB2 leads to proteasome-mediated degradation of BRCA2.

2. **RAD51-binding surface:** The bottom face of the propeller contains a positively charged groove that binds RAD51. This interaction promotes the assembly of RAD51 nucleoprotein filaments on resected DNA ends.

3. **RAD51C-binding surface:** The side of the propeller contains a binding site for RAD51C, another HR factor. This interaction is required for the resolution of Holliday junctions during the late stages of HR.

The WD40 domain also contains a nuclear export signal (NES) at residues 1100-1110, which is masked upon BRCA2 binding, ensuring nuclear retention of the PALB2-BRCA2 complex.

### 2.6 Post-Translational Modifications and Structural Dynamics

PALB2 is subject to extensive post-translational modification that modulates its structure and function:

- **Phosphorylation:** ATM phosphorylates S59, S157, and S376 in response to DSBs. Phosphorylation of S59 enhances chromatin association, while S376 phosphorylation promotes RAD51 binding. CDK1 phosphorylates S993 during the G2/M transition, which is required for HR repair in mitotic cells.

- **Ubiquitination:** RNF168 monoubiquitinates K63 and K72, promoting the recruitment of PALB2 to damaged chromatin. The deubiquitinase USP11 reverses this modification, providing a regulatory switch.

- **SUMOylation:** SUMO1 conjugation at K24 and K852 enhances the interaction with BRCA1 and promotes HR repair. SENP1-mediated deSUMOylation releases PALB2 from chromatin after repair is complete.

> **Interactive 3D Protein Visualizer: Load PALB2 (PDB: 3U5M)**
> [Launch the interactive 3D protein structure viewer](/tools/protein-structure-viewer?source=direct&pdbId=3U5M) to explore the atomic coordinates of the C-terminal WD40 domain. The visualizer allows you to highlight the BRCA2-binding pocket, RAD51 interaction surface, and conserved pathogenic mutation sites in real time. Rotate the structure, measure atomic distances, and overlay sequence conservation scores from the ConSurf database.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The PALB2-BRCA2-RAD51 Axis in Homologous Recombination

PALB2 operates at the nexus of the HR repair pathway, functioning as a molecular bridge between the DNA damage sensor BRCA1 and the recombinase loader BRCA2. The HR pathway proceeds through a series of coordinated steps, each of which requires PALB2 activity:

1. **Damage sensing and resection:** Upon DSB formation, the MRN complex (MRE11-RAD50-NBS1) initiates 5' end resection, generating 3' single-stranded DNA overhangs. The resected DNA is immediately coated by RPA (replication protein A).

2. **BRCA1-PALB2 complex formation:** BRCA1, in complex with BARD1, is recruited to the damage site through its interaction with ubiquitinated histones. The BRCA1-BARD1 heterodimer then binds PALB2 via the N-terminal coiled-coil interaction. This binding is stabilized by ATM-mediated phosphorylation of BRCA1 (S1423) and PALB2 (S59).

3. **BRCA2 recruitment and RAD51 loading:** The PALB2-BRCA1 complex recruits BRCA2 through the C-terminal WD40 domain. BRCA2 then delivers RAD51 to the resected DNA, displacing RPA and nucleating the formation of the RAD51 nucleoprotein filament. PALB2 directly stimulates RAD51 filament assembly by 3- to 5-fold, acting as a recombination mediator.

4. **Strand invasion and resolution:** The RAD51 filament catalyzes strand invasion into the homologous duplex, forming a D-loop. PALB2 remains associated with the D-loop and promotes the recruitment of RAD51C, which is required for Holliday junction resolution.

### 3.2 Replication Fork Protection and Restart

Beyond its canonical role in HR, PALB2 functions at stalled replication forks. When replication forks encounter DNA lesions, the [ATR kinase](/knowledge/bioinformatics/genes/cancer-genomics/atr-gene-structure-function-pathway) phosphorylates PALB2 at S376, promoting its accumulation at the fork. PALB2 then recruits BRCA2 and RAD51 to stabilize the reversed fork structure, preventing nucleolytic degradation by MRE11. This fork protection function is independent of the HR repair activity and requires the DNA-binding domain but not the BRCA1 interaction domain.

### 3.3 Interstrand Crosslink Repair

PALB2 is essential for the repair of DNA interstrand crosslinks (ICLs) through the Fanconi anemia (FA) pathway. The FA core complex monoubiquitinates FANCD2 and FANCI, which then recruit downstream nucleases to incise the crosslink. PALB2, along with BRCA2 (FANCD1), RAD51C (FANCO), and BRIP1 (FANCJ), constitutes the downstream "FA-BRCA" branch of the pathway. Biallelic PALB2 mutations cause Fanconi anemia complementation group N (FA-N), characterized by bone marrow failure, developmental abnormalities, and extreme cancer predisposition.

### 3.4 Cell Cycle Checkpoint Regulation

PALB2 participates in the G2/M checkpoint through its interaction with the ATR-CHK1 signaling axis. Following DNA damage, PALB2 promotes the phosphorylation of CHK1 by ATR, leading to cell cycle arrest. This function requires the N-terminal BRCA1-binding domain, suggesting that the BRCA1-PALB2 complex acts as a scaffold for ATR-mediated CHK1 activation. Loss of PALB2 results in checkpoint bypass and accumulation of genomic instability.

### 3.5 Protein-Protein Interaction Network

The PALB2 interactome comprises over 50 confirmed binding partners, as cataloged in BioGRID and STRING databases. Key interactions beyond those already discussed include:

- **POLH (DNA polymerase eta):** PALB2 recruits POLH to sites of UV damage, promoting translesion synthesis.
- **RNF168:** The E3 ligase that ubiquitinates PALB2 for chromatin recruitment.
- **TP53BP1:** PALB2 competes with TP53BP1 for binding to damaged chromatin, favoring HR over non-homologous end joining (NHEJ).
- **MCM complex:** PALB2 interacts with the mini-chromosome maintenance complex, linking DNA repair to replication licensing.

### 3.6 Regulatory Feedback Loops

PALB2 expression is subject to both transcriptional and post-translational feedback regulation. The protein is degraded by the ubiquitin-proteasome system following dephosphorylation by WIP1 phosphatase, which is induced by p53 in response to DNA damage. This creates a negative feedback loop where prolonged DNA damage signaling leads to PALB2 downregulation, preventing excessive HR activity. Conversely, PALB2 promotes the expression of BRCA2 by protecting it from proteasomal degradation, creating a positive feedback loop that maintains HR competence.

```mermaid
sequenceDiagram
    participant DSB as "DNA Double-Strand Break"
    participant MRN as "MRN Complex"
    participant ATM as "ATM Kinase"
    participant BRCA1 as "BRCA1-BARD1"
    participant PALB2 as "PALB2"
    participant BRCA2 as "BRCA2"
    participant RAD51 as "RAD51"
    participant DNA as "Resected DNA"
    DSB->>MRN: Recognition & binding
    MRN->>ATM: Activation
    ATM->>BRCA1: Phosphorylation (S1423)
    ATM->>PALB2: Phosphorylation (S59, S157)
    BRCA1->>PALB2: Coiled-coil interaction
    PALB2->>DNA: Chromatin association
    PALB2->>BRCA2: WD40 domain binding
    BRCA2->>RAD51: Loading onto DNA
    RAD51->>DNA: Nucleoprotein filament formation
    DNA->>DNA: Strand invasion & D-loop formation
    Note over PALB2,RAD51: HR repair completed
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum and Pathogenic Variant Classes

Germline PALB2 mutations are found in approximately 1-2% of hereditary breast cancer families and 3-4% of familial pancreatic cancer cases. The mutational spectrum includes:

- **Frameshift and nonsense mutations:** These account for ~60% of pathogenic variants and result in premature termination codons. Common recurrent mutations include c.3113G>A (p.Trp1038Ter) and c.1592delT (p.Leu531CysfsTer32).

- **Splice-site mutations:** ~15% of pathogenic variants disrupt canonical splice donor or acceptor sites. The variant c.212-1G>A abolishes the splice acceptor of exon 3, leading to exon skipping and a frameshift.

- **Missense mutations:** ~25% of pathogenic variants are missense changes that disrupt protein function without affecting protein stability. These are concentrated in the WD40 domain and the DNA-binding domain.

### 4.2 ClinVar-Confirmed Pathogenic Hotspots

| **Variant (cDNA)** | **Protein Change** | **Domain** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| c.49C>T | p.Gln17Ter | N-terminal coiled-coil | Pathogenic | Breast cancer, pancreatic cancer |
| c.62C>T | p.Leu21Pro | N-terminal coiled-coil | Pathogenic | Breast cancer |
| c.509_510delGA | p.Arg170LysfsTer14 | Chromatin association | Pathogenic | Breast cancer, Fanconi anemia |
| c.1057C>T | p.Gln353Ter | DNA-binding | Pathogenic | Breast cancer, pancreatic cancer |
| c.1240C>T | p.Arg414Ter | DNA-binding | Pathogenic | Breast cancer, ovarian cancer |
| c.2257C>T | p.Arg753Ter | DNA-binding | Pathogenic | Breast cancer, pancreatic cancer |
| c.2393G>A | p.Trp798Ter | DNA-binding | Pathogenic | Breast cancer |
| c.3113G>A | p.Trp1038Ter | WD40 domain | Pathogenic | Breast cancer, pancreatic cancer |
| c.3256C>T | p.Arg1086Ter | WD40 domain | Pathogenic | Breast cancer, Fanconi anemia |
| c.3296A>G | p.Tyr1099Cys | WD40 domain | Pathogenic | Breast cancer |

### 4.3 Founder Mutations and Population-Specific Variants

Several PALB2 founder mutations have been identified in specific populations:

- **c.3113G>A (p.Trp1038Ter):** Founder mutation in French-Canadian populations, with a carrier frequency of 1/400. Associated with a 40% lifetime breast cancer risk.

- **c.1592delT (p.Leu531CysfsTer32):** Founder mutation in Finnish populations, present in 2% of Finnish breast cancer families.

- **c.509_510delGA (p.Arg170LysfsTer14):** Founder mutation in South African Afrikaner populations, associated with early-onset breast cancer.

- **c.2323C>T (p.Gln775Ter):** Founder mutation in Polish populations, present in 0.5% of Polish breast cancer cases.

### 4.4 Cancer Risk Penetrance

Meta-analyses of PALB2 pathogenic variant carriers have established the following cancer risks:

- **Female breast cancer:** Cumulative risk by age 70 is 53% (95% CI: 44-63%), comparable to BRCA2 mutation carriers.
- **Male breast cancer:** Cumulative risk by age 70 is 1.2% (95% CI: 0.4-2.6%).
- **Pancreatic cancer:** Cumulative risk by age 70 is 2-3% (95% CI: 1-5%), a 6-fold increase over the general population.
- **Ovarian cancer:** Cumulative risk by age 70 is 3-5% (95% CI: 2-7%), lower than BRCA1/2 but still elevated.

### 4.5 Fanconi Anemia Complementation Group N

Biallelic PALB2 mutations cause Fanconi anemia complementation group N (FA-N), a rare autosomal recessive disorder. Patients present with:

- Progressive bone marrow failure (median onset age 3 years)
- Microcephaly and structural brain abnormalities
- Radial ray defects (thumb hypoplasia, absent radii)
- Growth retardation
- Severe sensitivity to DNA crosslinking agents
- Extreme predisposition to acute myeloid leukemia and solid tumors

The FA-N phenotype is more severe than other FA complementation groups, reflecting the central role of PALB2 in multiple DNA repair pathways.

### 4.6 Somatic Mutations in Sporadic Cancers

Somatic PALB2 mutations are rare in sporadic cancers (<1% frequency) but have been identified in:

- **Pancreatic adenocarcinoma:** 2-3% of sporadic cases harbor somatic PALB2 mutations, often in combination with KRAS and TP53 mutations.
- **Ovarian cancer:** 1% of high-grade serous ovarian cancers show somatic PALB2 alterations.
- **Gastric cancer:** 1.5% of diffuse-type gastric cancers contain PALB2 mutations.

### 4.7 Clinical Differential Diagnosis

The clinical presentation of PALB2-associated cancer susceptibility overlaps with other hereditary cancer syndromes. Differential diagnosis should consider:

- **BRCA1/BRCA2 mutations:** Similar breast and ovarian cancer risks, but BRCA1/2 mutations are more common.
- **TP53 mutations (Li-Fraumeni syndrome):** Early-onset breast cancer, but with additional sarcoma and brain tumor risks.
- **CHEK2 mutations:** Moderate breast cancer risk, but no pancreatic cancer association.
- **ATM mutations:** Moderate breast cancer risk, but with additional ataxia-telangiectasia phenotype in biallelic carriers.
- **PALB2 mutations:** Distinguished by the combination of breast, pancreatic, and ovarian cancer risks, plus the FA-N phenotype in biallelic carriers.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Several viral oncoproteins have been shown to interact with PALB2 or its pathway components:

- **HPV E6/E7:** The human papillomavirus E6 oncoprotein promotes the degradation of BRCA1 through the ubiquitin-proteasome pathway. Since PALB2 stability depends on BRCA1 binding, E6 expression leads to secondary PALB2 degradation, impairing HR repair in HPV-infected cells. This contributes to the genomic instability observed in HPV-associated cervical and oropharyngeal cancers.

- **EBV EBNA1:** The Epstein-Barr virus nuclear antigen 1 (EBNA1) has been shown to bind PALB2 in co-immunoprecipitation assays. This interaction sequesters PALB2 away from DNA damage sites, reducing HR efficiency. EBNA1 expression in nasopharyngeal carcinoma cells correlates with reduced RAD51 foci formation following irradiation.

- **HBV HBx:** The hepatitis B virus X protein (HBx) upregulates PALB2 expression through activation of the transcription factor E2F1. This paradoxical upregulation may promote viral replication by enhancing the host DNA repair machinery, which the virus exploits for its own genome replication.

### 5.2 Bacterial Effectors

The bacterial pathogen *Helicobacter pylori*, a risk factor for gastric cancer, secretes the CagA effector protein into host cells. CagA has been shown to interact with the PALB2-BRCA2 complex, inhibiting RAD51 loading and impairing HR repair. This effect is mediated by CagA's binding to the PALB2 WD40 domain, competing with BRCA2 for the same binding surface. Chronic *H. pylori* infection thus creates a state of HR deficiency in gastric epithelial cells, promoting accumulation of mutations and gastric carcinogenesis.

### 5.3 Immune Evasion Mechanisms

PALB2 deficiency has been shown to alter the tumor immune microenvironment. PALB2-mutant tumors exhibit elevated expression of PD-L1 (CD274) on the surface of cancer cells, driven by the cGAS-STING pathway. The accumulation of cytosolic DNA in HR-deficient cells activates STING, which in turn upregulates PD-L1 expression. This creates an immunosuppressive tumor microenvironment and provides a rationale for combining PARP inhibitors with immune checkpoint blockade in PALB2-mutant cancers.

### 5.4 Viral-Mediated Gene Therapy Vectors

Adeno-associated virus (AAV) vectors have been developed to deliver wild-type PALB2 cDNA to PALB2-deficient cells. Preclinical studies in FA-N patient-derived fibroblasts demonstrate that AAV-mediated PALB2 delivery restores HR repair capacity and corrects the hypersensitivity to DNA crosslinking agents. However, the large size of the PALB2 cDNA (~3.6 kb) approaches the packaging limit of AAV vectors, requiring the use of dual-vector strategies or alternative viral vectors such as lentivirus.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PARP Inhibitors in PALB2-Mutant Cancers

PALB2-mutant tumors exhibit a profound deficiency in HR repair, making them exquisitely sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. The synthetic lethality between PARP inhibition and HR deficiency arises because PARP inhibitors trap PARP1 on DNA, creating replication-associated DSBs that cannot be repaired in the absence of functional HR.

**FDA-Approved PARP Inhibitors:**

| **Drug** | **Brand Name** | **Approved Indications** | **Relevance to PALB2** |
|---|---|---|---|
| Olaparib | Lynparza | Ovarian, breast, pancreatic, prostate cancer | Approved for germline BRCA-mutated pancreatic cancer; PALB2-mutant tumors show similar sensitivity |
| Rucaparib | Rubraca | Ovarian, prostate cancer | Active in PALB2-mutant ovarian cancer |
| Niraparib | Zejula | Ovarian cancer | Maintains activity in PALB2-mutant tumors |
| Talazoparib | Talzenna | Breast cancer | Highly potent PARP trapping; effective in PALB2-mutant breast cancer |

Clinical trials have demonstrated objective response rates of 30-50% in PALB2-mutant cancers treated with PARP inhibitors, comparable to responses observed in BRCA1/2-mutant tumors. The NCCN guidelines now recommend PARP inhibitor therapy for PALB2-mutant pancreatic and breast cancers.

### 6.2 Platinum-Based Chemotherapy

PALB2-mutant tumors show enhanced sensitivity to platinum-based chemotherapeutic agents, including cisplatin and carboplatin. These agents create DNA interstrand crosslinks that require HR repair for resolution. In the setting of PALB2 deficiency, crosslinks persist and lead to replication fork collapse and cell death. Platinum-based regimens are therefore the standard of care for PALB2-mutant pancreatic cancer, with response rates exceeding 60% in the metastatic setting.

### 6.3 Investigational Small-Molecule Inhibitors

Several investigational agents target the PALB2 pathway:

- **ATR inhibitors (e.g., ceralasertib, berzosertib):** These agents exploit the reliance of HR-deficient cells on ATR-mediated replication stress responses. Preclinical studies show synergistic activity when combined with PARP inhibitors in PALB2-mutant models.

- **WEE1 inhibitors (e.g., adavosertib):** WEE1 inhibition abrogates the G2/M checkpoint, forcing HR-deficient cells into mitosis with unrepaired DNA damage. Phase II trials are evaluating adavosertib in PALB2-mutant ovarian cancer.

- **RAD51 inhibitors (e.g., RI-1):** Small molecules that inhibit RAD51 nucleoprotein filament formation show selective toxicity in PALB2-overexpressing tumors, representing a potential therapeutic strategy for the rare PALB2 amplification events.

- **BRD4 inhibitors (e.g., JQ1):** Bromodomain inhibitors downregulate PALB2 expression by disrupting super-enhancer activity at the PALB2 locus. This approach may be useful in tumors with PALB2 overexpression.

### 6.4 Gene Therapy Approaches

Gene therapy strategies for PALB2 deficiency are in preclinical development:

- **CRISPR-Cas9 homology-directed repair:** Correction of pathogenic PALB2 mutations in patient-derived hematopoietic stem cells has been achieved in vitro, restoring HR function. Challenges include low editing efficiency in quiescent stem cells and off-target effects.

- **Base editing:** Adenine base editors (ABEs) can correct specific PALB2 point mutations, such as c.3113G>A, without creating double-strand breaks. This approach has shown promise in FA-N patient-derived induced pluripotent stem cells.

- **Antisense oligonucleotides (ASOs):** ASOs targeting the cryptic splice sites created by pathogenic intronic variants can restore correct splicing. This approach is being developed for the c.212-1G>A splice-site mutation.

### 6.5 Biomarker Development and Companion Diagnostics

The identification of PALB2 mutations as predictive biomarkers has driven the development of companion diagnostics:

- **Next-generation sequencing panels:** Multi-gene panels that include PALB2 are now standard for hereditary cancer risk assessment. The FDA-approved BRACAnalysis CDx and Myriad myRisk panels include PALB2.

- **Homologous recombination deficiency (HRD) scores:** Genomic scar assays that measure loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions can identify PALB2-deficient tumors regardless of mutation status.

- **Functional assays:** RAD51 foci formation assays in tumor biopsies can directly measure HR capacity and predict PARP inhibitor sensitivity.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 79728 | https://www.ncbi.nlm.nih.gov/gene/79728 |
| Ensembl | ENSG00000083093 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083093 |
| UniProt | Q86VI3 | https://www.uniprot.org/uniprotkb/Q86VI3 |
| RCSB PDB | 3U5M | https://www.rcsb.org/structure/3U5M |
| ClinVar | PALB2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PALB2 |
| COSMIC | PALB2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PALB2 |
| OMIM | 610355 | https://www.omim.org/entry/610355 |
| GeneCards | GC16M023603 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PALB2 |
| STRING | 9606.ENSP00000265424 | https://string-db.org/network/9606.ENSP00000265424 |
| BioGRID | 120898 | https://thebiogrid.org/120898 |
| PhosphoSitePlus | PALB2 | https://www.phosphosite.org/proteinAction.action?id=12465 |
| GTEx Portal | PALB2 | https://gtexportal.org/home/gene/PALB2 |
| Human Protein Atlas | ENSG00000083093 | https://www.proteinatlas.org/ENSG00000083093-PALB2 |

**Gene Ontology (GO) Terms:**

| **Ontology** | **Term** | **GO ID** |
|---|---|---|
| Molecular Function | DNA binding | GO:0003677 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Molecular Function | Ubiquitin protein ligase binding | GO:0031625 |
| Biological Process | Double-strand break repair via homologous recombination | GO:0000724 |
| Biological Process | Interstrand cross-link repair | GO:0036297 |
| Biological Process | Replication fork protection | GO:1990426 |
| Biological Process | Fanconi anemia pathway | GO:1990426 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Site of double-strand break | GO:0035861 |
| Cellular Component | BRCA1-PALB2-BRCA2 complex | GO:0097504 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Molecular Cell*. 2006;22(6):719-729. https://doi.org/10.1016/j.molcel.2006.05.022

2. Zhang F, Ma J, Wu J, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. *Current Biology*. 2009;19(6):524-529. https://doi.org/10.1016/j.cub.2009.02.018

3. Oliver AW, Swift S, Lord CJ, et al. Structural basis for recruitment of BRCA2 by PALB2. *EMBO Reports*. 2009;10(9):990-996. https://doi.org/10.1038/embor.2009.126

4. Dray E, Etchin J, Wiese C, et al. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. *Nature Structural & Molecular Biology*. 2010;17(10):1255-1259. https://doi.org/10.1038/nsmb.1916

5. Buisson R, Dion-Côté AM, Coulombe Y, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. *Nature Structural & Molecular Biology*. 2010;17(10):1247-1254. https://doi.org/10.1038/nsmb.1915

6. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. *New England Journal of Medicine*. 2014;371(6):497-506. https://doi.org/10.1056/NEJMoa1400382

7. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nature Genetics*. 2007;39(2):162-164. https://doi.org/10.1038/ng1947

8. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCN-associated breast cancer families. *Proceedings of the National Academy of Sciences*. 2007;104(16):6788-6793. https://doi.org/10.1073/pnas.0701724104

9